Humana Drops Pay-For-Delay Claims Against Boehringer

Law360, New York (June 16, 2017, 6:30 PM EDT) -- Boehringer Ingelheim Pharma GmbH & Co. KG and Boehringer Ingelheim International GmbH & Co. on Friday reached an agreement with Humana Inc. in Connecticut federal court to dismiss Humana’s antitrust claims related to the pharmaceutical company’s alleged role in a scheme to block generic alternatives for its stroke-prevention drug Aggrenox.

The suit is part of multidistrict litigation accusing Barr Pharmaceuticals Inc., which was acquired by Teva Pharmaceutical Industries Ltd. in 2008, of agreeing to delay marketing its generic version of Aggrenox in exchange for a portion...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.